Cargando…

CSF beta-amyloid 1–42 – what are we measuring in Alzheimer's disease?

OBJECTIVE: To characterize biological and technical factors which influence cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarker levels, including the presence of apolipoprotein E (APOE) ε4 allele, AD diagnosis, Aβ-binding proteins, sample processing, and preanalytical handling. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, William T, Watts, Kelly D, Shaw, Leslie M, Howell, Jennifer C, Trojanowski, John Q, Basra, Sundeep, Glass, Jonathan D, Lah, James J, Levey, Allan I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338954/ https://www.ncbi.nlm.nih.gov/pubmed/25750918 http://dx.doi.org/10.1002/acn3.160

Ejemplares similares

Automation vs. Experience: Measuring Alzheimer’s Beta-Amyloid 1–42 Peptide in the CSF
por: Kollhoff, Alexander L., et al.
Publicado: (2018)

CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders
por: Mattsson, N, et al.
Publicado: (2013)

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2014)

Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
por: Toledo, Jon B, et al.
Publicado: (2013)

CSF complement 3 and factor H are staging biomarkers in Alzheimer’s disease
por: Hu, William T., et al.
Publicado: (2016)

Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease
por: Gangishetti, Umesh, et al.
Publicado: (2018)

Derivation of cutoffs for the Elecsys(®) amyloid β (1–42) assay in Alzheimer's disease
por: Shaw, Leslie M., et al.
Publicado: (2018)

Higher CSF sTREM2 and microglia activation are associated with slower rates of beta‐amyloid accumulation
por: Ewers, Michael, et al.
Publicado: (2020)

Phosphorylated tau/amyloid beta 1-42 ratio in ventricular cerebrospinal fluid reflects outcome in idiopathic normal pressure hydrocephalus
por: Patel, Sunil, et al.
Publicado: (2012)

Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays
por: Blennow, Kaj, et al.
Publicado: (2019)

Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology
por: Sandelius, Åsa, et al.
Publicado: (2018)

Lower CSF Amyloid-Beta(1–42) Predicts a Higher Mortality Rate in Frontotemporal Dementia
por: Vieira, Daniela, et al.
Publicado: (2019)

Targeting Beta-Amyloid at the CSF: A New Therapeutic Strategy in Alzheimer’s Disease
por: Menendez-Gonzalez, Manuel, et al.
Publicado: (2018)

Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays
por: van Harten, Argonde C., et al.
Publicado: (2021)

An association of CSF apolipoprotein E glycosylation and amyloid-beta 42 in individuals who carry the APOE4 allele
por: Meuret, Cristiana J., et al.
Publicado: (2023)

CSF-Targeted Proteomics Indicate Amyloid-Beta Ratios in Patients with Alzheimer's Dementia Spectrum
por: Behzad, Maryam, et al.
Publicado: (2023)

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
por: Hansson, Oskar, et al.
Publicado: (2019)

Patients with Alzheimer’s disease have an increased removal rate of soluble beta-amyloid-42
por: Zaretsky, Dmitry V., et al.
Publicado: (2022)

Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology
por: Suárez-Calvet, Marc, et al.
Publicado: (2019)

CSF biomarkers of Alzheimer’s disease concord with amyloid-β PETand predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
por: Hansson, Oskar, et al.
Publicado: (2018)

Presenilin 1 transgene addition to amyloid precursor protein overexpressing transgenic rats increases amyloid beta 42 levels and results in loss of memory retention
por: Agca, Cansu, et al.
Publicado: (2016)

Normalization of CSF pTau measurement by Aβ(40) improves its performance as a biomarker of Alzheimer’s disease
por: Guo, Tengfei, et al.
Publicado: (2020)

Noncanonical regulation of imprinted gene Igf2 by amyloid-beta 1–42 in Alzheimer’s disease
por: Fertan, Emre, et al.
Publicado: (2023)

Tyramine and Amyloid Beta 42: A Toxic Synergy
por: Dhakal, Sudip, et al.
Publicado: (2020)

AFM Probing of Amyloid-Beta 42 Dimers and Trimers
por: Maity, Sibaprasad, et al.
Publicado: (2020)

Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer’s disease
por: Borkowski, Kamil, et al.
Publicado: (2021)

Comparison of the amyloid pore forming properties of rat and human Alzheimer’s beta-amyloid peptide 1-42: Calcium imaging data
por: Di Scala, Coralie, et al.
Publicado: (2016)

A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease
por: Van der Auwera, Ingrid, et al.
Publicado: (2005)

Amyloid-beta transporter expression at the blood-CSF barrier is age-dependent
por: Pascale, Crissey L, et al.
Publicado: (2011)

Amyloid-beta 42 adsorption following serial tube transfer
por: Toombs, Jamie, et al.
Publicado: (2014)

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease
por: Jack, Clifford R., et al.
Publicado: (2010)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
por: Campbell, Michelle R., et al.
Publicado: (2021)

Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia
por: Oh, Esther S., et al.
Publicado: (2018)

Development of transgenic rats producing human β-amyloid precursor protein as a model for Alzheimer's disease: Transgene and endogenous APP genes are regulated tissue-specifically
por: Agca, Cansu, et al.
Publicado: (2008)

Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β ((1-42)), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop
por: Teunissen, Charlotte E., et al.
Publicado: (2010)

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
por: Alcolea, Daniel, et al.
Publicado: (2019)

Decreased CSF clearance and increased brain amyloid in Alzheimer’s disease
por: Li, Yi, et al.
Publicado: (2022)

Interaction of CSF α‐synuclein and amyloid beta in cognition and cortical atrophy
por: Lee, Young‐gun, et al.
Publicado: (2021)

Utility of an improved model of amyloid-beta (Aβ(1-42)) toxicity in Caenorhabditis elegans for drug screening for Alzheimer’s disease
por: McColl, Gawain, et al.
Publicado: (2012)

Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy
por: de Kort, Anna M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_be7voe2v1egfu2jpn3a8lmmj00